rs28933978 — OTC R141Q (Arg141Gln)

OTC R141Q — When the Urea Cycle's Gatekeeper Fails

Every gram of dietary protein you digest produces ammonia — a neurotoxin that must be captured and converted to urea within minutes or it will damage the brain. The enzyme that performs this critical capture step is ornithine transcarbamylase (OTC), which combines ammonia (as carbamoyl phosphate) with ornithine to form citrulline, the first committed step of the urea cycle¹¹ urea cycle
The urea cycle is a five-enzyme sequence in liver cells that converts toxic ammonia into water-soluble urea for urinary excretion. OTC performs the rate-limiting step. OMIM #311250. OTC deficiency is the most common inherited urea cycle disorder, occurring in approximately 1 in 14,000 live births.

The R141Q variant (c.422G>A, NM_000531.6) substitutes glutamine for the arginine at position 141 of the OTC protein. This arginine sits directly in the catalytic active site; its guanidinium side chain makes essential contacts with the carbamoyl phosphate substrate. Replacing it with glutamine's shorter, uncharged amide eliminates all enzymatic activity while leaving the protein structurally intact — the mutant protein folds correctly, is imported into the mitochondrion, and accumulates at normal concentrations, but cannot catalyze the reaction. ClinVar VCV000010987²² ClinVar VCV000010987 classifies it as pathogenic based on multiple submitters with no conflicts.

Because OTC is X-linked, males and females are affected in fundamentally different ways. Males have only one X chromosome, so one mutant allele means zero OTC activity in the liver. Females have two X chromosomes, and random X-inactivation³³ X-inactivation
In each cell of a female body, one X chromosome is randomly silenced. Female OTC carriers are therefore mosaics: some liver cells express normal OTC, others express R141Q. The balance between these two populations determines disease severity and can vary dramatically between women in the same family determines what fraction of liver cells retain functional OTC — producing a wide spectrum from fully asymptomatic to severe recurrent crises.

The Mechanism

Arginine 141 contributes two hydrogen bonds to carbamoyl phosphate in the OTC active site. Glutamine's side chain can donate one hydrogen bond but lacks the guanidinium group's ionic character, destroying the precise geometry needed for catalysis. Expression studies by Augustin et al. 2000⁴⁴ Augustin et al. 2000
Augustin L et al. Expression of wild-type and mutant human OTC genes in Chinese hamster ovary cells. Pediatr Res, 2000 confirmed that the R141Q protein accumulates at wild-type levels in transfected cells but shows zero OTC enzyme activity. Critically, when wild-type and R141Q protein were coexpressed together, the mutant showed no dominant negative effect — each R141Q molecule simply contributes nothing to the catalytic pool.

Without OTC activity, carbamoyl phosphate cannot enter the urea cycle and overflows into the pyrimidine synthesis pathway, producing orotic acid. Elevated urinary orotic acid is therefore the biochemical signature of OTC deficiency and is amplified by the allopurinol challenge test — a diagnostic tool that stresses the pyrimidine pathway and unmasks even partial OTC deficiency in female carriers.

The Evidence

In neonatal males with hemizygous R141Q, the clinical course is catastrophic. Infants appear normal at birth but by days 2–3 of life develop rapid ammonia accumulation (typically >200–500 µmol/L, often >1,000 µmol/L in severe cases). Without immediate intervention — nitrogen scavengers, dialysis, protein elimination — cerebral edema and death follow within hours to days. The Tuchman 1998 spectrum review⁵⁵ Tuchman 1998 spectrum review
Tuchman M et al. The biochemical and molecular spectrum of OTC deficiency. J Inherit Metab Dis, 1998 identifies R141Q as causing "neonatal disease" through active-site disruption, distinguishing it from mutations that produce milder late-onset phenotypes by different mechanisms.

In heterozygous females, the picture is strikingly heterogeneous. Ahrens et al. 1996⁶⁶ Ahrens et al. 1996
Ahrens MJ et al. Clinical and biochemical heterogeneity in females of a large pedigree with OTC deficiency due to the R141Q mutation. Am J Med Genet, 1996 studied 11 females in a large R141Q family and found that 5 of 7 confirmed carriers were symptomatic — a higher rate than traditionally estimated — yet none had elevated plasma ammonia on random testing. Three had markedly elevated plasma glutamine (a sensitive indirect marker of ammonia load); five tested positive for orotic aciduria either spontaneously or following allopurinol challenge. All five symptomatic carriers had remained undiagnosed for years. The Nguyen et al. 2020⁷⁷ Nguyen et al. 2020
Nguyen HH et al. Late-onset OTC deficiency and variable phenotypes in Vietnamese females. Front Pediatr, 2020 series estimated that 15–20% of female carriers present with late-onset symptoms triggered by metabolic stress.

Triggers for acute decompensation in female carriers include: high-protein meals, febrile illness, fasting, surgery, and most critically, the peripartum period. Lamb et al. 2013⁸⁸ Lamb et al. 2013
Lamb S et al. Multidisciplinary management of OTC deficiency in pregnancy. BMJ Case Reports, 2013 reported that pregnancy triggers "potentially fatal hyperammonemic crises" in OTC-deficient women. Successful management through delivery required sodium benzoate 4 g four times daily, sodium phenylbutyrate 2 g four times daily, arginine supplementation, and continuous protein restriction throughout gestation and postpartum.

A Spanish multicenter registry of 104 urea cycle disorder patients (Martín-Hernández et al. 2014⁹⁹ Martín-Hernández et al. 2014
Martín-Hernández E et al. Urea cycle disorders in Spain. Orphanet J Rare Dis, 2014) found that 63% of newly presenting patients experienced hyperammonemic encephalopathy at first crisis, with median peak ammonia of 298 µmol/L; 52.5% subsequently developed neurological sequelae. Early diagnosis — ideally before the first crisis — transforms outcomes.

Practical Actions

For males (hemizygous): Neonatal screening programs (NBS) in many countries include OTC deficiency. Confirmed hemizygous neonates require immediate specialist metabolic care: acute hyperammonemia is managed with IV glucose (to suppress catabolism), IV sodium phenylacetate/benzoate loading, and continuous renal replacement therapy (CVVHD) for severe elevations. Long-term management rests on protein restriction (0.5–1.0 g/kg/day in adults, higher in infants), oral nitrogen scavengers (sodium phenylbutyrate or glycerol phenylbutyrate), and L-arginine supplementation (to replenish the product the cycle cannot make). Liver transplantation, typically before age 6 months in severe neonatal cases, eliminates hyperammonemia risk and allows unrestricted diet — though pre-existing neurological damage is not reversed.

For females (heterozygous carriers): The majority remain asymptomatic under normal conditions but should know their key triggers (protein loading, fasting, fever, surgery, postpartum state). Women with a history of protein intolerance, unexplained migraine-like episodes, episodic confusion, or post-illness encephalopathy should have plasma ammonia and urinary orotic acid measured during or immediately after an episode. The GeneReviews protocol (Lichter-Konecki et al. 2022¹⁰¹⁰ Lichter-Konecki et al. 2022
GeneReviews OTC Deficiency, 2013/2022) recommends metabolic specialist involvement at first diagnosis regardless of current symptom status.

Interactions

OTC deficiency exists within the broader urea cycle pathway. Reduced ornithine availability from lysinuric protein intolerance (SLC7A7 deficiency) can compound OTC dysfunction since ornithine is the substrate that OTC normally processes. In heterozygous females, X-inactivation pattern is the primary modifier of clinical severity — skewed inactivation toward the R141Q-bearing chromosome produces more severe disease, and this is not detectable from standard genotype data alone. There are no documented pharmacogenomic drug interactions specific to OTC R141Q; however, valproate must be strictly avoided in OTC-deficient patients of both sexes, as it inhibits residual OTC activity and precipitates life-threatening hyperammonemia even at therapeutic doses.